Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ruffatti, A; Tonello, M; Hoxha, A; Sciascia, S; Cuadrado, MJ; Latino, JO; Udry, S; Reshetnyak, T; Costedoat-Chalumeau, N; Morel, N; Marozio, L; Tincani, A; Andreoli, L; Haladyj, E; Meroni, PL; Gerosa, M; Alijotas-Reig, J; Tenti, S; Mayer-Pickel, K; Simchen, MJ; Bertero, MT; De Carolis, S; Ramoni, V; Mekinian, A; Grandone, E; Maina, A; Serrano, F; Pengo, V; Khamashta, MA.
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Thromb Haemost. 2018; 118(4):639-646
Doi: 10.1055/s-0038-1632388
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mayer-Pickel Karoline Ilse
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy. The study's inclusion criteria were (1) positivity to lupus anticoagulant alone or associated with anticardiolipin and/or anti-β2 glycoprotein I antibodies; (2) a history of severe maternal-foetal complications (Group I) or a history of one or more pregnancies refractory to conventional therapy leading to unexplained foetal deaths not associated with severe maternal-foetal complications (Group II). Two different additional treatments were considered: oral-low-dose steroids (10-20 mg prednisone daily) and/or 200 to 400 mg daily doses of hydroxychloroquine and parenteral-intravenous immunoglobulins at 2 g/kg per month and/or plasma exchange. The study's primary outcomes were live birth rates and pregnancy complications. A total of 194 pregnant PAPS patients attending 20 tertiary centres were retrospectively enrolled. Hydroxychloroquine was found to be linked to a significantly higher live birth rate with respect to the other oral treatments in the Group II patients. The high (400 mg) versus low (200 mg) doses of hydroxychloroquine (p = 0.036) and its administration before versus during pregnancy (p = 0.021) were associated with a significantly higher live birth rate. Hydroxychloroquine therapy appeared particularly efficacious in the PAPS patients without previous thrombosis. Parenteral treatments were associated with a significantly higher live birth rate with respect to the oral ones (p = 0.037), particularly in the Group I patients. In conclusion, some additional treatments were found to be safe and efficacious in high-risk PAPS pregnant women. Schattauer GmbH Stuttgart.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Adult -
- Antibodies, Anticardiolipin - blood
- Antibodies, Antiphospholipid - blood
- Antiphospholipid Syndrome - therapy
- Birth Rate -
- Combined Modality Therapy -
- Female -
- Humans -
- Hydroxychloroquine - therapeutic use
- Immunoglobulins, Intravenous - therapeutic use
- Live Birth -
- Lupus Coagulation Inhibitor - blood
- Plasma Exchange -
- Pregnancy -
- Pregnancy Complications - drug therapy
- Pregnancy Outcome -
- Retrospective Studies -
- Risk -
- Steroids - administration & dosage
- Steroids - therapeutic use
- Thrombosis - drug therapy
- Find related publications in this database (Keywords)
- antiphospholipid syndrome
- hydroxychloroquine
- low-dose steroids
- intravenous immunoglobulins
- plasma exchange